Search Results
Mar 04, 2026, 08:31 ET Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program
regulatory documentation ahead of IND submission.HT-KIT results below have shown success in rare cancers Potent gene-level target suppression: HT-KIT achieved >80% reduction of KIT mRNA/protein across in-vitro systems and in vivo models of systemic mastocytosis
More news about: Hoth Therapeutics, Inc.
Mar 04, 2026, 08:00 ET Minaris Launches AgentSCREEN Adventitious Virus Detection by NGS to Simplify Viral Safety Testing for Cell Banks and Cell-Based Samples
supportPHILADELPHIA, March 4, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider, today announced the launch of
More news about: Minaris Advanced Therapies
Mar 04, 2026, 08:00 ET KLOTHO NEUROSCIENCES ACQUIRES GREENLAND MINES CORP., SECURING CONTROL OF A $68 BILLION PALLADIUM, GOLD, PLATINUM, AND CRITICAL MINERAL DEPOSIT IN THE WORLD'S MOST STRATEGICALLY VITAL EMERGING TRADE CORRIDOR
operating divisions: (1) Natural Resources, focused on the exploration and development of the Skaergaard Project in Southeast Greenland; and 2) Cell and Gene Therapy, including Klotho's KLTO-202 primary indication for ALS.
More news about: Klotho Neurosciences, Inc.
Mar 04, 2026, 07:05 ET REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Steven Foltz, Ph.D., Principal Scientist, Gene Therapy Research at REGENXBIOThe presentations will be available in the Publications section of REGENXBIO's website.REGENXBIO will also host a symposium titled, "Advancing Duchenne Gene Therapy Trials in a New Era: Optimizing Design
More news about: REGENXBIO Inc.
Mar 04, 2026, 07:00 ET HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting
IRF5 inhibitors, including the demonstration of dose-dependent inhibition of key pathway markers, including cytokine production and interferon and IRF5 gene signatures," said Geraldine Harriman, PhD, Co-Founder and Chief Scientific Officer of HotSpot Therapeutics. "These preclinical data provide strong support
More news about: HotSpot Therapeutics
Mar 04, 2026, 07:00 ET GALLO Selects Horizon Media as Agency of Record to Support Brand Growth Across Portfolio
working relationship together.""GALLO is home to a remarkably broad portfolio, each brand with its own unique story and consumer base," said Gene Turner, President, Global Chief Client Officer, Horizon Media. "We're committed to supporting GALLO as they continue to grow, helping to align investment
More news about: Horizon Media
Mar 03, 2026, 22:49 ET MGI Tech Announces Acquisition of STOmics and CycloneSEQ to Deliver Integrated Long-Read, Short-Read and Spatial Omics Solutions
service facilities globally.MGI stands out as one of the few companies capable of independently developing and mass-producing clinical-grade gene sequencers with varying throughput capacities, ranging from Gb to Tb levels. With unparalleled expertise, cutting-edge products, and a commitment to
More news about: MGI TECH
Mar 03, 2026, 21:00 ET Gene Solutions Announces Strategic Entry into Türkiye with Robust Real-World Evidence at the 2nd International Hereditary Cancers Congress 2026
TR-EEMEA-CIS, Gene Solutions. "Our multi-omics platforms and growing clinical evidence base reflect our commitment to improving outcomes for patients with hereditary and high-risk cancer while supporting localized, scalable implementation.""We are proud to partner with Gene Solutions to expand
More news about: Gene Solutions Genomics Pte Ltd
Mar 03, 2026, 16:20 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 03, 2026, 16:05 ET Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results
Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially
More news about: Cryoport, Inc.
Mar 03, 2026, 16:05 ET Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR::ABL gene fusion, the oncogenic driver for patients with CML.The Company
More news about: Enliven Therapeutics, Inc.
Mar 03, 2026, 14:36 ET Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.
faces a higher risk of hematologic cancers, further enlarges the addressable patient pool. At the same time, developers are advancing immunotherapies, gene therapies, and CAR-T cell therapies, improving clinical outcomes and supporting revenue expansion.Pharmaceutical manufacturers, research institutions,
More news about: Credence Research Inc.
Mar 03, 2026, 14:00 ET ISCT-JSRM 5-Year Joint Strategic Collaboration on Clinical iPSCs Launches Inaugural Joint Collaboration in Kobe, Japan - March 21, 2026
International Society for Cell & Gene TherapyEstablished in 1992, the International Society for Cell & Gene Therapy (ISCT) is a global society of clinicians, regulators, researchers, technologists, and industry partners with a shared vision to translate cell and gene therapy into safe and effective
More news about: International Society for Cell & Gene Therapy
Mar 03, 2026, 10:02 ET Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
broader cell and gene therapy sector is forecast to surge from $10.4 billion to more than $45 billion by 2035, with North America commanding over half the global market as clinical pipelines mature and reimbursement pathways solidify[3]. With more than 40 FDA-approved cell and gene therapy products
More news about: USA News Group
Mar 03, 2026, 10:00 ET The Mark Foundation Announces $4M in 2026 Drug Discovery Awards
Dana-Farber Cancer InstituteTargeting the proteins fueling leukemia and lung cancer to develop a more effective way to treat cancers driven by faulty gene expression.For more information on the Drug Discovery Award program and the 2026 recipients, visit
More news about: The Mark Foundation for Cancer Research
Mar 03, 2026, 09:45 ET 30th Edition of MCG Care Guidelines Reflects Advances in Evidence-Based Medicine and AI-Enabled Content
Trusted leader in clinical guidance releases new updates for cardiovascular surgery, gene therapy, and orthopedic proceduresSEATTLE, March 3, 2026 /PRNewswire/ --
More news about: MCG Health
Mar 03, 2026, 09:30 ET HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
panel convening investors and strategics at the forefront of the cell and gene therapy revolution. Panelists Robert Balfour of ALSA Ventures and Bettina Ernst of BERNINA BioInvest highlighted the current momentum in cell and gene therapies, discussed how they assess technical and commercial risk, identified
More news about: Harvest Integrated Research Organization (HiRO)
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
REPROCELLREPROCELL provides integrated stem cell, gene editing, and GMP manufacturing solutions supporting the entire path from discovery to clinical translation. With clinical grade iPSC generation (StemRNA™ Clinical iPSC), StemEdit gene editing, and GMP banking capability, REPROCELL serves academic,
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
REPROCELLREPROCELL provides integrated stem cell, gene editing, and GMP manufacturing solutions supporting the entire path from discovery to clinical translation. With clinical grade iPSC generation (StemRNA™ Clinical iPSC), StemEdit gene editing, and GMP banking capability, REPROCELL serves academic,
More news about: REPROCELL USA
Mar 03, 2026, 09:00 ET ALORA Appoints Adam Helms as CEO; Secures Funding from Grantham Environmental Trust and Toyota Ventures
company develops gene edited traits that shifts a crop's energy from defense to yieldNORWICH RESEARCH PARK, England, March 3, 2026 /PRNewswire/ -- ALORA, an agricultural biotechnology company developing gene-edited crop traits
More news about: ALORA Innovations Inc.
Mar 03, 2026, 09:00 ET ALORA Appoints Adam Helms as CEO; Secures Funding from Grantham Environmental Trust and Toyota Ventures
company develops gene edited traits that shifts a crop's energy from defense to yieldNORWICH RESEARCH PARK, England, March 3, 2026 /PRNewswire/ -- ALORA, an agricultural biotechnology company developing gene-edited crop traits
More news about: ALORA Innovations Inc.
Mar 03, 2026, 09:00 ET Shareholders that lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: The Gross Law Firm
Mar 03, 2026, 09:00 ET Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
and age-related disease prevention — is projected to grow from under $100 million in 2025 to nearly $3 billion by 2040. As research into senolytics, gene therapies, and regenerative medicine accelerates, companies are moving beyond supplements and skincare into science-backed pharmaceutical solutions.
More news about: Market News Updates
Mar 03, 2026, 08:30 ET Evaluating the Impact of Cell Culture Supplements on CHO Clonal Outgrowth Efficiency, Upcoming Webinar Hosted by Xtalks
March 3, 2026 /PRNewswire/ -- The generation of clonal cell lines is a fundamental component of the biomanufacturing of protein, cellular and gene therapies. However, single-cell cloning can introduce risks due to low cell viability and potential delays to cell line development workflows, particularly
More news about: Xtalks
Mar 03, 2026, 07:00 ET SpliSense Granted EMA EARLY PRIME Designation for SPL84 in Cystic Fibrosis
Priority Medicines (e-PRIME) designation to SPL84 for the treatment of cystic fibrosis (CF) in patients carrying the 3849+10Kb C>T mutation in the CFTR gene. The e-PRIME designation follows a review by the Committee for Medicinal Products for Human Use (CHMP), which recognized the remaining unmet medical
More news about: Splisense